ライフサイエンスコーパス: human serum

1 dia (saliva with 5%, 10%, or 20% inactivated human serum).

2 uracy of 98.9% in PBS, and 100% in undiluted human serum.

3 on HDL and albumin when it is incubated with human serum.

4 as optimized, and stability was evaluated in human serum.

5 or point-of-care diagnostics with samples of human serum.

6 or in vitro detection of Abeta aggregates in human serum.

7 nfirmed in a background of minimally diluted human serum.

8 ctrometry for rapid quantitation of 25OHD in human serum.

9 n (nanomolar range) in complex media such as human serum.

10 essfully applied to the detection of CD56 in human serum.

11 Extracellular RNAs (exRNAs) are present in human serum.

12 and furthermore 58 glycans are enriched from human serum.

13 causes prolongation of aptamer stability in human serum.

14 ) to quantify 25-hydroxyvitamin D (25OHD) in human serum.

15 om as low as 100 fg/mL of analytes spiked in human serum.

16 els containing only bovine synovial fluid or human serum.

17 gel was used for the analysis of proteins in human serum.

18 yrylcholinesterase enzyme (BChE) activity in human serum.

19 assays or background drift correction in 50% human serum.

20 ted by measuring Zika antigen in a simulated human serum.

21 evels of SRM 972a are composed of unmodified human serum.

22 a hemolymph, and also had a growth defect in human serum.

23 yolk and phospholipids/phosphopeptides from human serum.

24 tide alone, and showed enhanced stability in human serum.

25 to quantify glucose in honey, white wine and human serum.

26 ith macrophage colony-stimulating factor and human serum.

27 of the LIS device for detecting L-Alanine in human serum.

28 uit C1-INH to their surfaces when exposed to human serum.

29 selectivity that allowed us to detect LYS in human serum.

30 irectly measuring biological samples such as human serum.

31 abilized against degradation by nucleases in human serum.

32 more sensitive to beta-lactam antibiotics in human serum.

33 e mouse serum samples and a curated panel of human serum.

34 fHbp and promotes survival of N. cinerea in human serum.

35 ssfully identified from 161 glycoproteins in human serum.

36 lpha9alpha10 nAChR and improved stability in human serum.

37 ed enrichment of N-linked glycopeptides from human serum.

38 ation formats such as cell culture media and human serum.

39 mug/mL and operating well in the presence of human serum.

40 4) CFU/mL were successfully performed in 25% human serum.

41 concomitant with its inability to survive in human serum.

42 of zika, dengue, and chikungunya virus from human serum.

43 r MIC in this tissue culture medium with 20% human serum.

44 diotracers were immunoreactive and stable in human serum.

45 he mechanisms of these processes in mice and human serum.

46 to quantify 14 antiepileptic drugs (AEDs) in human serum.

47 ilieu of immune response proteins present in human serum.

48 entrations; and retains its functionality in human serum.

49 ce the minute amounts of absorbed Ara h 2 in human serum.

50 determine the level of Ara h 2 absorption in human serum.

51 y and retains its immunoreactive capacity in human serum.

52 formance of the designed system in undiluted human serum.

53 Bovine milk and human serum (25 muL) spiked with a mixture of methyl-, e

54 enrichment of PSA from a complex matrix of a human serum; 5) direct incubation of anti-PSA modified M

55 Under human serum AB or M-CSF, only monocytes from RA had a de

56 thmic BoNT/A concentrations in PBS, milk and human serum across a 0.27-268pgmL(-1) range and associat

57 3-LAHLA is the most abundant LAHLA isomer in human serum after ingestion of liposomes made of fractio

58 y depleting highly abundant proteins such as human serum albumin (>10(10) more abundant than cTnI).

59 ml PSA as high as 7-fold increase versus the human serum albumin (HSA) and 8-fold increase versus the

60 ntify pH-dependent conformational changes in human serum albumin (HSA) and cytochrome C by monitoring

61 ities towards the target biomarker proteins (human serum albumin (HSA) and human immunoglobulin G (HI

62 ermodynamics and kinetics of binding between human serum albumin (HSA) and resveratrol (RES) or its a

63 hierarchical structure for determination of human serum albumin (HSA) are designed and fabricated.

64 is study was to investigate the potential of human serum albumin (HSA) as a solubilising agent/drug d

65 resence of a high concentration (500 muM) of human serum albumin (HSA) as an interfering protein in t

66 The knowledge on human serum albumin (HSA) binding is of utmost importanc

67 These additives interaction with human serum albumin (HSA) can exert considerable effect

68 Previously, we showed that human serum albumin (HSA) can increase foreign DNA acqui

69 cused on bovine serum albumin (BSA), leaving human serum albumin (HSA) comparatively understudied.

70 ein nanoparticle (SPNP) based on polymerized human serum albumin (HSA) equipped with the cell-penetra

71 to human A2, C1, and C2 domains presented as human serum albumin (HSA) fusion proteins.

72 The label-free detection of human serum albumin (HSA) in aqueous buffer is demonstra

73 rize chemically induced protein unfolding of human serum albumin (HSA) in great detail.

74 Quantitative and selective detection of human serum albumin (HSA) is demonstrated with a limit o

75 finity for PSMA and appropriate affinity for human serum albumin (HSA) may demonstrate a higher thera

76 e of solution chemistry on the adsorption of human serum albumin (HSA) proteins on graphene oxide (GO

77 ally determined binding affinity of DOX with human serum albumin (HSA) was considered to simplify the

78 cyanate (FITC) after fluorescent labeling of human serum albumin (HSA) with electromembrane extractio

79 on of complexes with albumin (in particular, human serum albumin (HSA)) are fundamental for the chara

80 human glutathione S-transferase pi (hGSTP), human serum albumin (HSA), and bovine serum albumin (BSA

81 by additives, such as Triton X-100 (TX) and human serum albumin (HSA), are not fully understood.

82 abundantly expressed extracellular protein, human serum albumin (HSA), inhibits alphaS oligomer (alp

83 , in the presence of physiological levels of human serum albumin (HSA), the r(1) relaxivity is amplif

84 enous inhibitor of Abeta self-association is human serum albumin (HSA), which binds approximately 90%

85 llenges, we rationally developed a drug-free human serum albumin (HSA)-based therapeutic (KH-1) that

86 e molecular details for the interaction with human serum albumin (HSA).

87 rug readily forms a noncovalent complex with human serum albumin (HSA).

88 s onto proteins to increase their binding to human serum albumin (HSA).

89 detecting catechol estrogens (CEs)-adducted human serum albumin (HSA).

90 antages of unusually long serum half-life of human serum albumin (HSA).

91 tose and l-ascorbic acid were incubated with human serum albumin (HSA).

92 librium dissociation constant for Zn(2+) and human serum albumin (Kd = (5.62 +/- 0.93) x 10(-7) M) un

93 -relevant delivery systems (liposomes and in human serum albumin [HSA]-fusion products) in combinatio

94 The ability to detect miRNA-21 in human serum albumin and bovine serum albumin was almost

95 Using human serum albumin as a model, its sequence was exploit

96 e was identified by X-ray crystallography in human serum albumin at drug site 3, which is also known

97 Human serum albumin binding was measured by affinity hig

98 icals, medium-to-low lipophilicity, and high human serum albumin binding.

99 Median human serum albumin for OriCols was 14.9 mug/ml, whereas

100 Human serum albumin is an endogenous ligand transport pr

101 Conjugation of fatty acid, a natural human serum albumin ligand, to a therapeutic protein/pep

102 Addition of a human serum albumin molecule prolongs the half-life in a

103 Noncovalent binding of biopharmaceuticals to human serum albumin protects against enzymatic degradati

104 er, lapatinib release from a nanoshell-based human serum albumin protein host complex resulted in inc

105 of the emodin and aloe-emodin derivatives to human serum albumin ranged from -7.30 and -10.62 kcal/mo

106 whole blood was removed and replaced with 5% human serum albumin to reduce haemoglobin concentration

107 The addition of human serum albumin to the tri-specific inhibitor could

108 Here, we examine the binding of an ABD to human serum albumin using isothermal titration calorimet

109 an antibody binding site, HSA Peptide 40, on human serum albumin with nanomolar affinity for all thre

110 ter inhibition with a CCD inhibitor (MUXF(3)-human serum albumin).

111 ost completely removes p-cresyl sulfate from human serum albumin, a protein that these uremic toxins

112 1), 0.49 T, 37 degrees C) in the presence of human serum albumin, allowing a significant MRI signal i

113 The binding of JMS-053 to human serum albumin, however, did not markedly alter the

114 ds in lysozyme and all 17 disulfide bonds in human serum albumin, including nested disulfide bonds an

115 hosphatase 4A3 binds to at least one site on human serum albumin, which is likely to extend the compo

116 We focused on modifications to Cys34 in human serum albumin, which is responsible for scavenging

117 bound to lysines 195 and 475 of CLV-treated human serum albumin.

118 we determined that ATRAM binds reversibly to human serum albumin.

119 reaction of a pendant maleimide ligand with human serum albumin.

120 specific binding of bovine serum albumin and human serum albumin.

121 xchange chromatography based purification of human serum albumin.

122 ain antibody fragment specific for mouse and human serum albumin.

123 whole blood was removed and replaced with 5% human serum albumin.

124 titration calorimetry that JMS-053 binds to human serum albumin.

125 ELISA measurements in human serum also indicate distinct kinetics for PCSK6 in

126 3 N-glycosylation sites were identified from human serum and 149 glycopeptides derived from 129 glyco

127 es spiked with exosomes derived from healthy human serum and a prostate cancer cell line.

128 nstrated to provide robust quantification in human serum and are shown to be compatible with each of

129 tocol, along with quantitative recoveries in human serum and bacteria cultures.

130 Direct detection of EVs in human serum and cell culture medium without tedious samp

131 ed each member of this library for growth in human serum and discovered 178 mutants with significant

132 terol and 17,20-dihydroxypregnalumisterol in human serum and epidermis, and the porcine adrenal gland

133 through the classical and lectin pathways in human serum and in mouse serum.

134 AuNPs in various analytical matrixes such as human serum and natural creek water (Highland Creek, ON)

135 ed with this approach, low interference from human serum and other proteases and good reproducibility

136 iron oxide core-shell nanoworms incubated in human serum and plasma are rapidly opsonized with the th

137 trate ficolin-2/-3 heterocomplexes in normal human serum and plasma by ELISA using Abs specific for f

138 sease 2019 (COVID-19)-specific antibodies in human serum and plasma.

139 ny formation, as well as reduced survival in human serum and reduced adherence to human cervical and

140 s 20 copies of Ebola virus templates in both human serum and saliva and could be adapted to distingui

141 the receptor binding domain of SARS-CoV-2 in human serum and saliva, and for quantifying immunoglobul

142 presence of other nontarget microorganisms, human serum and shellfish homogenate, supporting the pot

143 assay for measuring the activity of sCD73 in human serum and show a strong linear correlation between

144 PEG-LA) were unstable in fetal bovine serum, human serum and synovial fluid, with varying levels of i

145 ion, for the isolation of EVs from 200 ul of human serum and their separation from non-EV protein and

146 onstrated by the analysis of the alkaloid in human serum and urine samples.

147 ed for assessment of H(2)O(2) and glucose in human serum and urine samples.

148 targets in complex biological fluids such as human serum and urine.

149 reatly improved resistance to degradation in human serum and, surprisingly, displayed up to 52-fold h

150 challenged with either excess La(3+) ions or human serum, and did not accumulate in any organ after 5

151 PCB 11 and its metabolites are present in human serum, and emerging evidence demonstrates that PCB

152 tion by four different nucleases, bovine and human serum, and human urine.

153 Radiochemical stability was studied in human serum, and immunoreactivity was determined by cell

154 on of the peptide is biochemically stable in human serum, and most serum-stable fragments have full a

155 lycoprotein suspended in diluted PBS buffer, human serum, and plasma.

156 egative-ion mode to phospholipids present in human serum, and the data set was used to evaluate the v

157 d collectively promote Y. pestis survival in human serum, antibiotic resistance, and cell envelope in

158 Immunoglobulin G1 (IgG1), a subclass of human serum antibodies, is the most widely used scaffold

159 l (SRM) 972a Vitamin D Metabolites in Frozen Human Serum as a replacement for SRM 972, which is no lo

160 We were able to detect BPA spiked in human serum as well as in maternal and cord blood within

161 y applied to analyze the N-glycan changes in human serum associated with hepatocellular carcinoma (HC

162 on antigen-bearing lipid membranes by normal human serum at 4 degrees C.

163 ible to perform single-molecule screening in human serum at ultra-low protein concentrations.

164 , surface plasmon resonance, and competitive human serum bactericidal assay, which is a surrogate for

165 on, this method showed excellent recovery in human serum (between 80 and 120% for all analytes).

166 ne diseases by highly sensitive measuring in human serum both critical characteristics of autoantibod

167 fied standard solutions and 1 muL samples of human serum, both glycoproteins can be immunocaptured an

168 ssed in artificial interstitial fluid and in human serum, both spiked with lactate.

169 idespread environmental contaminant found in human serum, breastmilk, and other tissues, capable of l

170 TKO PBMCs was significantly greater than of human serum, but there was no significant difference bet

171 Despite, CRP antigen was further detected in human serum by spiking CRP to run-through the detection

172 cancer marker, in human serum by using easy and quickly prepared disposabl

173 like protein 22 (CDH22), a cancer marker, in human serum by using easy and quickly prepared disposabl

174 odies was enhanced in the presence of intact human serum complement or purified C3a or C5a.

175 onment and involved in the interactions with human serum components.

176 enotypes in E. coli, including resistance to human serum, cosedimentation of human vitronectin, and p

177 to quantify FC and CE in lipid extracts from human serum, cultured cells, and mouse liver.

178 uantitative detection of PSA in a buffer and human serum diluted 1/100.

179 y peptide scavenging, but T2D pancreatic and human serum EVs have no effect.

180 By probing human serum for the presence of anti-Cas9 antibodies usi

181 were analyzed in a secondary screen against human serum from healthy donors.

182 onally measured endogenous GM-CSF and IL6 in human serum from n = 14 human subjects using our mobile

183 Indeed, direct exposure of PCCL3 cells to human serum from two patients with Graves' disease, but

184 characterizing two abundant and well-studied human serum glycoproteins, alpha-1-antitrypsin and immun

185 ment of human galectin-3 (hGal-3C) and three human serum GPs, alpha-1-acid glycoprotein (AGP), haptog

186 erumoxytol was incubated in media containing human serum (group 1), fetal bovine serum (group 2), Ste

187 ) system for determination of transferrin in human serum has been developed.

188 Undiluted pooled human serum (HS) and five different commercial preparati

189 ies, which were able to block the binding of human serum IgE.

190 S aureus extracellular proteins targeted by human serum IgG4 were identified by means of immunoblott

191 Thirty-four glycopeptides from human serum immunoglobulin G (IgG) tryptic digests were

192 n detection limit of 38 muU/mul in 10% (v/v) human serum in a 5 min assay time.

193 extent and allowed the recognition of NSE in human serum in a concentration range of 25-4000 pg/mL.

194 Activity of alpha-amylase enzyme in human serum indicates the onset of pancreatitis, mumps,

195 Concentration of alpha-amylase in human serum is a key indicator of various pancreatic ail

196 Human serum is a rich source of readily accessible EVs;

197 eover, the practical determination of AFP in human serum is also investigated, demonstrating its appl

198 ly detected from a few hundred nanoliters of human serum loaded onto chromatography paper.

199 of a standardized mixed meal showed that the human serum metabolome is remarkably stable: The median

200 The intra-individual variability of the human serum metabolome over a period of 4 weeks and its

201 nvestigating the temporal variability of the human serum metabolome under such tightly controlled con

202 (TTR) concentration was highly increased in human serum of lung cancer patients.

203 cell-culture supernatant (and eventually in human serum) on magnetic particles modified with antibod

204 004 wt % of the total protein in 1:4 diluted human serum or 0.024 wt % of the total protein from brea

205 nalysis of more than 20 nonesterified FAs in human serum or plasma.

206 tifying C-reactive protein concentrations in human serum over a large portion of the physiological ra

207 roduced with taurolidine, hydrogen peroxide, human serum, potassium iodide and doxorubicin/ oxaliplat

208 ty in different in vitro models of VC (i.e., human serum, primary cell cultures, and tissue explants)

209 Apolipoprotein L1 (ApoL1) is a human serum protein conferring resistance to African try

210 rnal factors, such as glucose, ascorbic acid human serum protein, immunoglobulin G, and immunoglobuli

211 ased from several glycoprotein standards and human serum proteins, we demonstrated that the Y1 ion tr

212 demonstrated in the analysis of a certified human serum reference material yielding excellent accura

213 f Zika NS1 to be carried out in 10% and 100% human serum, respectively.

214 viruses in the presence of either a bNAb or human serum resulted in rapid expansion of the mutant.

215 We used human serum rigorously characterized to be sera from pat

216 When tested in a human serum sample between 25 and 43 degrees C, the sens

217 tra-high sensitivity detection in buffer and human serum sample down to 600 zM and 20 aM, respectivel

218 The determination of cytochrome c in the human serum sample is a regular medical investigation pe

219 Five sensor prototypes were tested in a human serum sample over one week and the maximum deviati

220 sed sensor was successfully used with spiked human serum sample with a limit of detection of 81 pM Th

221 of 105 +/- 4.1% obtained from a spiked, real human serum sample.

222 the algorithm is demonstrated for correcting human serum samples analyzed by Fourier-transform mass s

223 ulation data with antibody binding data from human serum samples demonstrated qualitative and quantit

224 dy design with dual approaches of collecting human serum samples for testing was developed.

225 We evaluated our results on human serum samples from lymphoma patients and healthy c

226 The target anti-p53aAbs from human serum samples is selectively isolated and purified

227 Testing of 192 human serum samples showed that DCL accurately identifie

228 ept, the technology platform was tested with human serum samples spiked with exosomes derived from he

229 All mouse and human serum samples that were able to neutralize rMuVJL5

230 work, a DNA biosensor to detect ZIKV in real human serum samples was developed using an oxidized glas

231 imultaneous detection of CA125 and CA15-3 in human serum samples was evaluated and the obtained resul

232 concentration values directly measured in 35 human serum samples were found closely correlated to tho

233 everal representative ionic metabolites from human serum samples were successfully quantified.

234 Combining small RNA sequencing from 179 human serum samples with a neural network analysis produ

235 d for the practical detection of H(2)O(2) in human serum samples with desirable properties.

236 detects the presence of Abeta aggregates in human serum samples with excellent sensitivity.

237 ssing West Nile viral IgM antibody levels in human serum samples yielding analyte detection limits co

238 lume in (~5 muL), performs sample cleanup on human serum samples, and delivers a small volume out, fo

239 )) of IgG antibody (CR3022) to SARS-CoV-2 in human serum samples, demonstrating the efficacy of these

240 7 (a tumor biomarker candidate) in undiluted human serum samples, operating with very low sample volu

241 was successfully applied in a cohort of 140 human serum samples, showing good sensitivity (64.6%) as

242 was successfully applied in a cohort of 127 human serum samples, showing good sensitivity (97.6%) as

243 emonstrated for its practical application in human serum samples, suggesting a promising application

244 can routinely measure PSA concentrations in human serum samples, very low concentrations have to be

245 sitivity and selectivity to quantify ZIKV in human serum samples, which suggests its promising clinic

246 d ALP between 108.84% and 172.50% (n = 3) in human serum samples.

247 d for the detection of NS1 DENV biomarker in human serum samples.

248 1 SRIG was demonstrated using (non-)clinical human serum samples.

249 s successfully used for NSE determination in human serum samples.

250 the label-free determining SCCA in clinical human serum samples.

251 er of heart failure, in buffer and untreated human serum samples.

252 sults for the detection of AMP in the spiked human serum samples.

253 ng the glucose and cholesterol level of real human serum samples.

254 y for detection of HER2 in complex matrix of human serum samples.

255 ed in post mortem human amygdala, as well as human serum samples.

256 ed, prompting a proof-of-concept analysis of human serum samples.

257 and tested the biochemical effects of CAR in human serum samples.

258 The linear range for thrombin detection in human serum solution is from 10 pM to 1 muM, with a regr

259 f added L-glutamate acid (50 and 100 muM) in human serum soup were 96.1% and 97.5% respectively.

260 potency, receptor selectivity, and enhanced human serum stability to target the human alpha9alpha10

261 These prodrugs showed excellent stability in human serum (t(1/2) > 12 h) and potent activation of Vga

262 ntly used to measure the cancer biomarker in human serum that allows detecting 12 times lower concent

263 nded for the detection of a model protein in human serum, that is, human immunoglobulin G, with the a

264 When S. pneumoniae D39 was opsonized with human serum, the larger C4 activation products C4b and i

265 particles as label for detection of CA125 in human serum through developed competitive ALFA.

266 , beta-caryophyllene, and alpha-humulene) in human serum to aid human-exposure investigations.

267 detection of multiplex cardiac biomarkers in human serum to expedite medical decisions for enhanced p

268 nveil the potential use of their quantity in human serum to mark the pathological elicitation of thes

269 ng of propofol, both in PBS and in undiluted human serum, to demonstrate that ML-based model solves e

270 rocedure significantly impacts EV yield from human serum, together with the presence of lipoprotein a

271 Human serum transferrin (hTF) is a central part of the t

272 ty for the detection of CEA even in the real human serum, upon which it is proposed for the early det

273 luated toward the sensing of APAP and INH in human serum, urine, saliva, and tablet samples.

274 etection of the cardiac marker troponin I in human serum using sample volumes of ~1 muL and with a li

275 ection of prostate specific antigen (PSA) in human serum using silicon nanowire field effect transist

276 deficient in incorporation of linoleate from human serum verifying the role of FakB3 in this process.

277 lebsiella pneumoniae, by B. bacteriovorus in human serum versus buffer.

278 Limit of detection of 1pg/mL in human serum was achieved for both cTnI and cTnT.

279 Neisseria meningitidis after incubation with human serum was completely C3-dependent, as detected by

280 s detection and quantification of HEV RNA in human serum was developed based on an adaptation of a pr

281 e four DENV serotypes spiked into 50% normal human serum was increased by at least a factor of 5 when

282 Overall, saliva with 5% human serum was optimal for replicating subgingival micr

283 roduced 6 h after the onset of chest pain in human serum, was possible.

284 Recoveries of these proteins from spiked human serum were 85-115% or better, depending slightly o

285 ults from determination of HIV DNA target in human serum were obtained showing great potential of the

286 rus, dengue virus, and chikungunya virus, in human serum were simultaneously detected on the all-in-o

287 ng the presence of CPS type-specific IgGs in human serum when sample volumes are limited and/or numer

288 ection of 10(5) exosomes muL(-1) directly in human serum, when performing the immunomagnetic separati

289 2 monoclonal antibody spiked into monkey and human serum, where lower limits of quantification (LLOQ)

290 ated fatty acids and glycerophospholipids in human serum, where uncommon isomers of low abundance wer

291 nM in phosphate-buffered saline and 5 nM in human serum, which are physiologically relevant concentr

292 nd successfully exploited to analyze SGPs in human serum, which highlighted the feasibility of this s

293 erol efflux to acceptor (apo)lipoprotein and human serum, while loss of TSPO resulted in impaired cho

294 The sensor could detect glucose in human serum with a detection limit of 1.25 nM and preser

295 itive detection of anti-SARS-CoV-2 S1 IgG in human serum with only 8 muL sample volume.

296 alysis of squamous cell carcinoma antigen in human serum with recoveries of 97.3%, 102.4% and 107.4%.

297 he selectivity of detecting cTnT and cTnI in human serum with wide dynamic range.

298 pro-brain natriuretic peptide (NT-proBNP) in human serum within its clinical range.

299 fully used in the quantification of CDH22 in human serum without any pretreatment.

300 r can directly detect the target microRNA in human serum without pretreatment.